Product Description
Matriks Biotek Shikari® Q-REMS Infliximab (Remsima®) ELISA has been especially developed for the quantitative analysis of free Infliximab (Remsima®) in serum and plasma samples.
Remsima®,the world first biosimilar mAb (approved in 2013 by EMA). The Agencys Committee for Medicinal Products for Human Use (CHMP) decided that, in accordance with EU requirements, Remsima® has been shown to have a comparable quality, safety and efficacy profile to Remicade®.
Specifications:
Required Volume (µl) | 10 |
Total Time (min) | 70 |
Sample | Serum, Plasma |
Sample Number | 96 |
Detection Limit (ng/mL) | 100 |
Spike Recovery (%) | Between 85-115 |
Shelf Life (year) | 1 |
Documentation
Download IFU
Download MSDS
Please note that the documentation provided is for reference use only. For the most updated version, please contact us.
For Research Use Only
Manufactured by Matriks Biotek Co.
Questions about this product? Ready to place an order? Email us at orders@iwai-chem.com or give us a call: (650) 486-1541 |